Nasdaq · CIK 0002007191
TLX Telix Pharmaceuticals Ltd
Insider trading from SEC Form 4. Last filing 29 d ago. Close $11.21 on Oct 9, 2026, +75% from the 52-week low and -13% from the high.
Telix Pharmaceuticals Ltd (TLX) has 2 SEC Form 4 filings on file from 2 insiders, the latest filed on Sep 14, 2026. In the last 90 days insiders made 1 open-market buy worth $20k and 0 open-market sells worth $0, net +$20k.
2 open-market trades have been scored at TLX. The newest: Darren Charlton Smith (Group Chief Financial Officer) bought $20k of stock on Sep 7, 2026, filed Sep 14, 2026, scored 25 (weak). The largest of the 2 shown: Christian Behrenbruch (MD & Group CEO) bought $997k on Apr 28, 2026, scored 53 (moderate).
TLX closed at $11.21 on Oct 9, 2026, 75% above its 52-week low and 13% below its 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Telix Pharmaceuticals Ltd, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 25Weak | Darren Charlton Smith Group Chief Financial Officer buy | $20k 2,071 shares | +17% | - | |
| 53Moderate | Christian Behrenbruch MD & Group CEO buy | $997k 67,935 shares | +0% | +63% from low-44% from high |
Transactions
Every row filed, 3 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 7, 2026 | Darren Charlton Smith Group Chief Financial Officer | POpen-market purchase Ordinary Shares | +2,071 | $9.66 | $20k | 13,992 | 29 d ago |
| Apr 28, 2026 | Christian Behrenbruch MD & Group CEO | POpen-market purchase Ordinary Sharesindirect: Elk River Holdings Pty Ltd | +34,500 | $14.48 | $500k | 20,709,500 | May 6, 2026 |
| Apr 29, 2026 | Christian Behrenbruch MD & Group CEO | POpen-market purchase Ordinary Sharesindirect: Elk River Holdings Pty Ltd | +33,435 | $14.87 | $497k | 20,742,935 | May 6, 2026 |
Insiders
Everyone who has filed a Form 4 here.
- Christian BehrenbruchMD & Group CEO
- Darren Charlton SmithGroup Chief Financial Officer
Questions about TLX
Answered from the filings on this page, as of the latest one.
Are insiders buying TLX?
As of Sep 14, 2026, SEC Form 4 filings show 1 open-market buy worth $20k by 1 insider and 0 open-market sells worth $0 by 0 insiders at Telix Pharmaceuticals Ltd in the last 90 days, net +$20k. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade TLX on the open market?
Darren Charlton Smith (Group Chief Financial Officer) bought $20k of TLX on Sep 7, 2026 and filed the Form 4 on Sep 14, 2026. InsiderTell scored 25 (weak).
How many insiders file Form 4 at Telix Pharmaceuticals Ltd?
2 people have filed a Form 4 at Telix Pharmaceuticals Ltd, among them Christian Behrenbruch (MD & Group CEO), Darren Charlton Smith (Group Chief Financial Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.